lamivudine HBV
Selected indexed studies
- Hepatitis B virus genetic multiplicity and the associated HBV lamivudine resistance mutations in HBV/HIV co-infection in Western Kenya: A review article. (Infect Genet Evol, 2022) [PMID:34954390]
- Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. (Int J Clin Pharm, 2016) [PMID:27450506]
- Lamivudine in the treatment of HBV-related liver disease after renal transplantation: an update. (Int J Artif Organs, 2005) [PMID:15818543]
_Worker-drafted node — pending editorial review._
Connections
lamivudine HBV is a side effect of
Sources
- Hepatitis B virus genetic multiplicity and the associated HBV lamivudine resistance mutations in HBV/HIV co-infection in Western Kenya: A review article. (2022) pubmed
- Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. (2016) pubmed
- Lamivudine in the treatment of HBV-related liver disease after renal transplantation: an update. (2005) pubmed
- Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. (2007) pubmed
- The relationship between HBV lamivudine resistance and HBV genotypes or basic core promoter mutations. (2003) pubmed
- Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation. (2004) pubmed
- Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. (2005) pubmed
- Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China. (2015) pubmed
- Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBV-producing cells. (2005) pubmed
- HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. (2000) pubmed